Work

Supp Fig S5 from MSH2 Loss in Primary Prostate Cancer

Year: 2023

Type: other

Abstract: PD-L1 immunostaining in tumors with MSH2 loss. Standard tissue sections of tumors with MSH2 protein loss shows PD-L1 immunolabeling in lymphocytes predominantly (22966), in lymphocytes and focally in tumor cells (61879) and in lymphocytes predominantly (71503). All photomicrographs are reduced from 200x.

DOI: 10.1158/1078-0432.22463730.v1

Authors: Liana B. Guedes, Emmanuel S. Antonarakis, Michael T. Schweizer, Nooshin Mirkheshti, Fawaz Almutairi, Jong Chul Park, Stephanie Glavaris, Jessica Hicks, Mario A. Eisenberger, Angelo M. De Marzo, Jonathan I. Epstein, William B. Isaacs, James R. Eshleman, Colin C. Pritchard, Tamara L. Lotan

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361922096

Cites:

Cited by:

Related to: 10